Drug intelligence / Profile preview

Mutant pro-urokinase (M5)

Development stage: Discontinued
Lead developer: Thrombolytic Science International
Modality: Recombinant Proteins and Enzymes
Administration: Intra-arterial, Intravenous

Overview

Mutant pro-urokinase (M5) is a thrombolytic drug, a modified form of single-chain urokinase-type plasminogen activator (pro-urokinase). It is engineered for improved plasma stability by reducing its intrinsic catalytic activity, allowing it to maintain its proenzyme form until it encounters a thrombus. Its two-chain enzymatic form (tcM5) is susceptible to inhibition by C1-inhibitor, which helps prevent non-specific plasminogen activation and associated bleeding complications.

Targets

PLG (Plasminogen)SERPING1 (Serpin family G member 1)

Beyond the preview

Go deeper on Mutant pro-urokinase (M5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mutant pro-urokinase (M5).

Explore the full profile